I started serious Investing Journey in Jan 2000 to create wealth through long-term investing and short-term trading; but as from April 2013 my Journey in Investing has changed to create Retirement Income for Life till 85 years old in 2041 for two persons over market cycles of Bull and Bear.

Since 2017 after retiring from full-time job as employee; I am moving towards Investing Nirvana - Freehold Investment Income for Life investing strategy where 100% of investment income from portfolio investment is cashed out to support household expenses i.e. not a single cent of re-investing!

It is 57% (2017 to Aug 2022) to the Land of Investing Nirvana - Freehold Income for Life!


Click to email CW8888 or Email ID : jacobng1@gmail.com



Welcome to Ministry of Wealth!

This blog is authored by an old multi-bagger blue chips stock picker uncle from HDB heartland!

"The market is not your mother. It consists of tough men and women who look for ways to take money away from you instead of pouring milk into your mouth." - Dr. Alexander Elder

"For the things we have to learn before we can do them, we learn by doing them." - Aristotle

It is here where I share with you how I did it! FREE Education in stock market wisdom.

Think Investing as Tug of War - Read more? Click and scroll down



Important Notice and Attention: If you are looking for such ideas; here is the wrong blog to visit.

Value Investing
Dividend/Income Investing
Technical Analysis and Charting
Stock Tips

Wednesday 25 July 2012

Biosensors' Q1 net profit up 45%, sees higher FY13 earnings

Biosensors International Group Ltd, a maker of medical devices, said on Wednesday that its net profit for the fiscal first quarter ended June 30, 2012 rose 45 per cent from a year ago to US$32.63 million.

The improved performance was due to the full quarter consolidation of the results of JW Medical System Ltd (JWMS) in the first quarter, higher product revenue, licensing revenue and gain on fair value adjustments for the derivatives.

Total revenue, including licensing and royalty revenue, rose 51 per cent from a year ago to US$86.31 million.

The management expects total revenues for thefiscal year ending March 31, 2013 to grow between 20% and 30%, driven by continued strong revenue growth from its drug-eluting stent (DES) as well as modest licensing and royalty revenue increase.


No comments:

Post a Comment

Related Posts with Thumbnails